

Product Data Sheet

Rovazolac

 Cat. No.:
 HY-109073

 CAS No.:
 1454288-88-0

 Molecular Formula:
 $C_{21}H_{19}F_3N_2O_4S$

Molecular Weight: 452.45
Target: LXR

Pathway: Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor

Storage: Powder -20°C 3 years

4°C 2 years

In solvent -80°C 2 years

-20°C 1 year

SOLVENT & SOLUBILITY

In Vitro

Ethanol: 10 mg/mL (22.10 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	2.2102 mL	11.0509 mL	22.1019 mL
	5 mM	0.4420 mL	2.2102 mL	4.4204 mL
	10 mM	0.2210 mL	1.1051 mL	2.2102 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% EtOH >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: \geq 2.5 mg/mL (5.53 mM); Clear solution
- 2. Add each solvent one by one: 10% EtOH >> 90% corn oil Solubility: ≥ 2.5 mg/mL (5.53 mM); Clear solution

BIOLOGICAL ACTIVITY

Description	Rovazolac is a liver x receptor (LXR) modulator extracted from patent WO2013130892A1.
IC ₅₀ & Target	Target: LXR ^[1]
In Vitro	Rovazolac is an anti-inflammatory drug candidate $^{[1]}$. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

1]. Mohan R. Preparation of substituted pyrazoles as liver X receptor (LXR) modulators useful for the treatment of dermal diseases, disorders and conditions. WO2013130892A1							
	Caution: Product has no	t been fully validated for me	edical applications. For research	use only.			
	Tel: 609-228-6898	Fax: 609-228-5909	E-mail: tech@MedChemExp	press.com			
	Address: 1 l	Deer Park Dr, Suite Q, Monmo	outh Junction, NJ 08852, USA				

Page 2 of 2 www.MedChemExpress.com